Research Article
Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson’s Disease Demonstrated by Proton Magnetic Resonance Spectroscopy
Table 4
Classification results from PLS-DA of intermediary metabolite levels in cerebrospinal fluid measured by proton magnetic resonance spectroscopy.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Asymptomatic mutation carriers: healthy individuals carrying the LRRK2 p.G2019S mutation; LVs: latent variables; random subsets, 10 divisions and 10 repetitions. Leave-one-out cross-validation. |